Primary immunodeficiencies (PIDs) are a group of more than 400 potentially serious disorders that can lead to frequent or severe infections, swellings and autoimmune problems. PIDs can be caused by defects in genes that control the immune system, and may be inherited.  

ASCIA Immunodeficiency Strategy for Australia and New Zealand To be launched in June 2021

Information for Patients, Consumers and Carers

Immunoglobulin replacement therapy (IRT)

SCIg therapy - general information for patients and carers  

Checklist - SCIg equipment  

Checklist - SCIg infusions

Fast Facts about primary immunodeficiency 

COVID-19 and Immunodeficiency 

COVID-19, Immunodeficiency and School Attendance   

Primary immunodeficiency (PIDs)

Severe combined immunodeficiency (SCID)

Common variable immunodeficiency (CVID)

Hereditary angiodema (HAE) - under development

Subcutaneous Immunogobulin (SCIg) Information 

SCIg therapy - general information for patients and carers 

SCIg information handouts for patients and carers (ASCIA member access only)

Guide - Setting up a SCIg service in a hospital 

SCIg Treatment Plan

Transfer Care Plan for patients on IRT (immunoglobulin replacement therapy)

Travel Plan for patients on SCIg (subcutaneous immunoglobulin) therapy 

SCIg Position Statement 

Other Information for Health Professionals

ASCIA Webinar - HAE 

Guidelines – Standardised infusion rates for intravenous immunoglobulin (IVIg) replacement therapy 

Primary immunodeficiencies (PID) Clinical Update 

Diagnosis and Management of Severe Combined Immunodeficiency (SCID) in Australia and New Zealand: A TAPID Consensus Guideline

Primary immunodeficiencies (PID) e-training 

Hereditary Angioedema (HAE) Position Paper and Management Plan  

ASCIA Immunodeficiency Strategy for Australia and New Zealand 

Content updated May 2021